Profile of alglucosidase alfa in the treatment of Pompe disease: safety, efficacy, and patient acceptability

References

• Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79(1):69–72.
   Web of Science ®Google Scholar
• Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7(6):713–716.
   Web of Science ®Google Scholar
• Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122(1):e39–e45.
   PubMed Web of Science ®Google Scholar
• Hobson-Webb LD, Proia AD, Thurberg BL, Banugaria S, Prater SN, Kishnani PS. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genetics Metab. 2012;106(4):462–469.
   Web of Science ®Google Scholar
• Katona I, Weis J, Hanisch F. Glycogenosome accumulation in the arrector pili muscle in Pompe disease. Orphanet J Rare Dis. 2014;9:17.
   Web of Science ®Google Scholar
• Di Rocco M, Buzzi D, Taro M. Glycogen storage disease type II: clinical overview. Acta Myol. 2007;26(1):42–44.
   Google Scholar
• Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–676.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144(Suppl 5):S35–S43.
   Web of Science ®Google Scholar
• Montagnese F, Barca E, Musumeci O, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968–978.
   Web of Science ®Google Scholar
• Musumeci O, la Marca G, Spada M et al. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. Journal of neurology, neurosurgery, and psychiatry. Epub 2015 Mar 17.
   Google Scholar
• Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252(8):875–884.
   Web of Science ®Google Scholar
• van der Beek NA, van Capelle CI, van der Velden-van Etten KI, et al. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genetics Metab. 2011;104(1–2):129–136.
   Web of Science ®Google Scholar
• Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009;19(2):113–117.
   Web of Science ®Google Scholar
• Hanisch F, Kronenberger C, Zierz S, Kornhuber M. The significance of pathological spontaneous activity in various myopathies. Clin Neurophysiol. 2014;125(7):1485–1490.
   Web of Science ®Google Scholar
• Kassardjian CD, Engel AG, Sorenson EJ. Electromyographic findings in 37 patients with adult-onset acid maltase deficiency. Muscle Nerve. 2015;51(5):759–761.
   Web of Science ®Google Scholar
• Horvath JJ, Austin SL, Case LE, et al. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in pompe disease. Muscle Nerve. 2015;51(5):722–730.
   PubMed Web of Science ®Google Scholar
• Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.
   PubMed Web of Science ®Google Scholar
• Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol. 2013;70(7):923–927.
   Web of Science ®Google Scholar
• Camelier M, De Mari J, Burin M, Civallero G, Giugliani R. Extended use of dried-leukocytes impregnated in filter paper samples for detection of Pompe, Gaucher, and Morquio A diseases. Clin Chim Acta Int J Clin Chem. 2015;446:218–220.
   Web of Science ®Google Scholar
• Spacil Z, Tatipaka H, Barcenas M, Scott CR, Turecek F, Gelb MH. High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin Chem. 2013;59(3):502–511.
   PubMed Web of Science ®Google Scholar
• Mechtler TP, Stary S, Metz TF, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335–341.
   PubMed Web of Science ®Google Scholar
• Paciotti S, Persichetti E, Pagliardini S, et al. First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta Int J Clin Chem. 2012;413(23–24):1827–1831.
   PubMed Web of Science ®Google Scholar
• Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genetics Metab. 2012;106(3):281–286.
   PubMed Web of Science ®Google Scholar
• Pompe Disease Diagnostic Working Group, Winchester B, Bali D, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genetics Metab. 2008;93(3):275–281.
   Web of Science ®Google Scholar
• Oba-Shinjo SM, da Silva R, Andrade FG, et al. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations. J Neurol. 2009;256(11):1881–1890.
   Web of Science ®Google Scholar
• Kroos M, Hoogeveen-Westerveld M, Michelakakis H, et al. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat. 2012;33(8):1161–1165.
   Web of Science ®Google Scholar
• De Filippi P, Saeidi K, Ravaglia S, et al. Genotype–phenotype correlation in Pompe disease, a step forward. Orphanet J Rare Dis. 2014;9:102.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Yang HW, Pennybacker M, et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest. 1998;101(4):827–833.
   Web of Science ®Google Scholar
• Raben N, Danon M, Gilbert AL, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genetics Metab. 2003;80(1–2):159–169.
   Web of Science ®Google Scholar
• Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med Off J Am Coll Med Genet. 2001;3(2):132–138.
   Google Scholar
• Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol. 2004;55(4):495–502.
   Web of Science ®Google Scholar
• FULL PRESCRIBING INFORMATION MYOZYME® (alglucosidase alfa); Genzyme Corporation, a Sanofi company. MZ-US-P090-03-14. Available from: https://www.myozyme.com. Accessed December 7, 2015.
   Google Scholar
• Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149(1):89–97.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329–335.
   PubMed Web of Science ®Google Scholar
• Levine JC, Kishnani PS, Chen YT, Herlong JR, Li JS. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol. 2008;29(6):1033–1042.
   Web of Science ®Google Scholar
• Hahn A, Praetorius S, Karabul N, et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65–75.
   PubMedGoogle Scholar
• Prater SN, Banugaria SG, DeArmey SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med Off J Am Coll Med Genet. 2012;14(9):800–810.
   Google Scholar
• Chien YH, Lee NC, Chen CA, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985–991, e981–e982.
   Web of Science ®Google Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genetics Metab. 2010;99(1):26–33.
   PubMed Web of Science ®Google Scholar
• van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inher Metab Dis. 2015;38(2):305–314.
   Web of Science ®Google Scholar
• Nayak S, Doerfler PA, Porvasnik SL, et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PloS One. 2014;9(6):e98336.
   Web of Science ®Google Scholar
• Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe’s disease. New Engl J Med. 2009;360(2):194–195.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med Off J Am Coll Med Genet. 2012;14(1):135–142.
   Google Scholar
• Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with pompe disease treated with alglucosidase alfa: a case report. JIMD Rep. 2012;2:11–15.
   Google Scholar
• Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med Off J Am Coll Med Genet. 2013;15(2):123–131.
   Google Scholar
• Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PloS One. 2013;8(6):e67052.
   Web of Science ®Google Scholar
• Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40–49.
   Web of Science ®Google Scholar
• Kanters TA, Hoogenboom-Plug I, Rutten-Van Molken MP, Redekop WK, van der Ploeg AT, Hakkaart L. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet J Rare Dis. 2014;9:75.
   Web of Science ®Google Scholar
• van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. New Engl J Med. 2010;362(15):1396–1406.
   PubMed Web of Science ®Google Scholar
• Gungor D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.
   PubMed Web of Science ®Google Scholar
• Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260(4):951–959.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Henley W, Wyatt KM, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inher Metab Dis. 2014;37(6):945–952.
   PubMed Web of Science ®Google Scholar
• Regnery C, Kornblum C, Hanisch F, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inher Metab Dis. 2012;35(5):837–845.
   PubMed Web of Science ®Google Scholar
• Andreassen CS, Schlutter JM, Vissing J, Andersen H. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease – a long-term follow-up. Mol Genetics Metab. 2014;112(1):40–43.
   Web of Science ®Google Scholar
• Gruhn KM, Heyer CM, Güttsches A-K, et al. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Mol Genetics Metab Rep. 2015;3(0):58–64.
   Google Scholar
• Deroma L, Guerra M, Sechi A, et al. Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study. Eur J Pediatr. 2014;173(6):805–813.
   Web of Science ®Google Scholar
• Echaniz-Laguna A, Carlier RY, Laloui K, et al. SHOULD patients with asymptomatic pompe disease be treated? A nationwide study in france. Muscle Nerve. 2015;51(6):884–889.
   Web of Science ®Google Scholar
• Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT. 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26–28 September 2014. Neuromusc Disorders. 25(8):674–678.
   Web of Science ®Google Scholar
• Raben N, Lu N, Nagaraju K, et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Human Mol Genetics. 2001;10(19):2039–2047.
   Web of Science ®Google Scholar
• Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics. 2008;5(4):569–578.
   Web of Science ®Google Scholar
• de Vries JM, van der Beek NA, Hop WC, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.
   Web of Science ®Google Scholar
• de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genetics Metab. 2010;101(4):338–345.
   PubMed Web of Science ®Google Scholar
• Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genetics Metab. 2012;106(3):301–309.
   Web of Science ®Google Scholar
• Schneider I, Deschauer M, Hanisch F. Enzyme replacement therapy and antibodies in late-onset Pompe disease. Mol Genetics Metab Reports. 2014;1(0):232–234.
   Google Scholar
• van der Meijden JC, Gungor D, Kruijshaar ME, Muir AD, Broekgaarden HA, van der Ploeg AT. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inher Metab Dis. 2015;38(3):495–503.
   Web of Science ®Google Scholar
• Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther J Am Soc Gene Therapy. 2009;17(6):954–963.
   PubMed Web of Science ®Google Scholar
• Sanofi, Genzyme aSC. Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01898364. Identifier: NCT01898364. Accessed November 24, 2015.
   Google Scholar
• Lun Y, Xu S, Gotschall R et al. Histological Examination of the Effect of a Highly Phosphorylated Proprietary Recombinant Human Acid α-Glucosidase on Glycogen Reduction in Disease-relevant Muscles of Pompe Mice. Available from: http://files.shareholder.com/downloads/AMTX/3343666038x0x808164/DAAA784E-E5E0-4642-A9C7-582953571737/Lun_et_al_Histological_Examination_of_Effect_of_Highly_Phosphorylated_Proprietary_Recombinant_Human_Acid_Alfa_Glucosidase.pdf. Accessed November 24, 2015.
   Google Scholar
• Koeberl DD, Austin S, Case LE, et al. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. FASEB J. 2014;28(5):2171–2176.
   Web of Science ®Google Scholar
• Farah BL, Madden L, Li S, et al. Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease. FASEB J. 2014;28(5):2272–2280.
   Web of Science ®Google Scholar
• Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genetics Metab. 2007;90(1):49–57.
   Web of Science ®Google Scholar
• Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1- deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009;30(12):1683–1692.
   PubMed Web of Science ®Google Scholar
• Parenti G, Fecarotta S, la Marca G, et al. A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther J Am Soc Gene Therapy. 2014;22(11):2004–2012.
   PubMed Web of Science ®Google Scholar
• Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther J Am Soc Gene Therapy. 2014;22(4):702–712.
   Web of Science ®Google Scholar
• Falk DJ, Mah CS, Soustek MS, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther J Am Soc Gene Therapy. 2013;21(9):1661–1667.
   PubMed Web of Science ®Google Scholar
• Qiu K, Falk DJ, Reier PJ, Byrne BJ, Fuller DD. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther J Am Soc Gene Therapy. 2012;20(1):21–27.
   Web of Science ®Google Scholar
• Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Human Mol Genetics. 2011;20(R1):R61–R68.
   PubMedGoogle Scholar
• Falk DJ, Soustek MS, Todd AG, et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev. 2015;2:15007.
   Web of Science ®Google Scholar
• Todd AG, McElroy JA, Grange RW, et al. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Annals of Neurology. 2015;78(2):222–234.
   Web of Science ®Google Scholar
• Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013;24(6):630–640.
   PubMed Web of Science ®Google Scholar
• Byrne PI, Collins S, Mah CC, et al. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev. 2014;25(3):134–163.
   PubMed Web of Science ®Google Scholar
• Savic N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2015. Epub 2015 Sep 26.
   Google Scholar
• Schuller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C(1):80–88.
   Web of Science ®Google Scholar
• Bandyopadhyay S, Wicklund M, Specht CS. Novel presentation of pompe disease: Inclusion body myositis-like clinical phenotype. Muscle Nerve. 2015;52(3):466–467.
   Web of Science ®Google Scholar
• Wens SC, Ciet P, Perez-Rovira A, et al. Lung MRI and impairment of diaphragmatic function in Pompe disease. BMC Pulm Med. 2015;15:54.
   Web of Science ®Google Scholar
• Schneider I, Hanisch F, Muller T, Schmidt B, Zierz S. Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Medizinisc Wochensch. 2013;163(1–2):40–44.
   Google Scholar
• Soliman OI, van der Beek NA, van Doorn PA, et al. Cardiac involvement in adults with Pompe disease. J Inter Med. 2008;264(4):333–339.
   Web of Science ®Google Scholar
• Roberts M, Kishnani PS, van der Ploeg AT, et al. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. Mol Genetics Metab. 2011;104(4):574–582.
   Web of Science ®Google Scholar
• Bertoldo F, Zappini F, Brigo M, et al. Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease. J Clin Endocrinol Metab. 2015;100(2):401–406.
   PubMed Web of Science ®Google Scholar
• Haaker G, Forst J, Forst R, Fujak A. Orthopedic management of patients with Pompe disease: a retrospective case series of 8 patients. Sci World J. 2014;2014:963861.
   Google Scholar
• van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inher Metab Dis. 2010;33(5):597–602.
   Web of Science ®Google Scholar
• Hanisch F, Rahne T, Plontke SK. Prevalence of hearing loss in patients with late-onset Pompe disease: Audiological and otological consequences. Int J Audiol. 2013;52(12):816–823.
   PubMed Web of Science ®Google Scholar
• Laforet P, Petiot P, Nicolino M, et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology. 2008;70(22):2063–2066.
   Web of Science ®Google Scholar
• Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve. 2011;44(6):897–901.
   Web of Science ®Google Scholar
• Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord. 2013;23(4):319–323.
   Web of Science ®Google Scholar
• Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I. Ptosis, extraocular motility disorder, and myopia as features of pompe disease. Orbit. 2011;30(2):111–113.
   PubMedGoogle Scholar
• Spiridigliozzi GA, Heller JH, Kishnani PS. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. Am J Med Genet C Semin Med Genet. 2012;160C(1):22–29.
   Web of Science ®Google Scholar
• Hobson-Webb LD, Austin SL, Jain S, Case LE, Greene K, Kishnani PS. Small-fiber neuropathy in pompe disease: first reported cases and prospective screening of a clinic cohort. Am J Case Rep. 2015;16:196–201.
   PubMed Web of Science ®Google Scholar
• But WM, Lee SH, Chan AO, Lau GT. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. Hong Kong Med J. 2009;15(6):474–477.
   Google Scholar
• Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inher Metab Dis. 2010;33(6):747–750.
   Web of Science ®Google Scholar
• Del Rizzo M, Fanin M, Cerutti A, et al. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report. J Inher Metab Dis. 2010;33(Suppl 3):S389–S393.
   Google Scholar
• Rohrbach M, Klein A, Kohli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inher Metab Dis. 2010;33(6):751–757.
   PubMed Web of Science ®Google Scholar
• Khallaf HH, Propst J, Geffrard S, Botha E, Pervaiz MA. CRIM-negative pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy. JIMD Rep. 2013;9:133–137.
   Google Scholar
• Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genetics Metab. 2012;105(4):677–680.
   Web of Science ®Google Scholar
• Cho A, Kim SJ, Lim BC, et al. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy. J Child Neurol. 2012;27(3):319–324.
   Web of Science ®Google Scholar
• Amartino HM, Cavagnari BM. [Enzyme replacement therapy in the infantile form of Pompe disease: Argentinean experience in a seven-year follow up case]. Arch Argent Pediatr. 2012;110(4):323–327. Spanish.
   Web of Science ®Google Scholar
• Fathalla W, Ahmed E. The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE. JIMD Rep. 2013;8:7–10.
   Google Scholar
• Markic J, Polic B, Stricevic L, et al. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr. 2014;126(3–4):133–137.
   Web of Science ®Google Scholar
• Isayama R, Shiga K, Seo K, et al. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy. J Clin Neuromusc Dis. 2014;15(4):152–156.
   Google Scholar
• Park JS, Kim HG, Shin JH, Choi YC, Kim DS. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2015;36(4):599–605.
   Google Scholar
• Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;259(5):952–958.
   PubMed Web of Science ®Google Scholar
• Furusawa Y, Mori-Yoshimura M, Yamamoto T, et al. Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study. J Inher Metab Dis. 2012;35(2):301–310.
   Web of Science ®Google Scholar
• Orlikowski D, Pellegrini N, Prigent H, et al. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord. 2011;21(7):477–482.
   Web of Science ®Google Scholar
• Bembi B, Pisa FE, Confalonieri M, et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inher Metab Dis. 2010;33(6):727–735.
   Web of Science ®Google Scholar
• Strothotte S, Strigl-Pill N, Grunert B, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2:12-month results of an observational clinical trial. J Neurol. 2010;257(1):91–97.
   PubMed Web of Science ®Google Scholar